Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2005

View Archived Issues

Close proximity of dopaminergic and serotonergic neurons might explain delayed effects of SSRIs

Antidiabetic effects of cytogenin in streptozotocin-induced diabetes in mice

A novel Stat3 inhibitor as a treatment for breast cancer

Pregabalin provides fast pain relief in postherpetic neuralgia

Promising results obtained with a novel formulation of dronabinol in healthy volunteers

Japanese approval for Vfend

Delay to sBLA filing for Erbitux

Enrollment under way in SYNTAX trial comparing stents to cardiac surgery

Enrollment begins in ENDEAVOR IV study

Osel initiates two Lactin-V phase II studies

Memory extends timeline for safety and tolerability study of MEM-1003

Provectus prepares to study Xantryl in psoriasis and eczema

Series A financing to support Janus pipeline progression

OMS-103HP enters phase III

7TM Pharma and P&G sign research agreement

Enrollment completed in TRIUMPH study of eculizumab for PNH

Phase I/II trial begins for SonoLysis in PAOD

Seattle Genetics inlicenses anti-CD33 antibody program from PDL

Schering-Plough to begin preclinical development of collaborative compound

Vectura and Arakis sign development deal with Novartis for AD-237 for COPD

Alnylam and Benitec sign license agreement in RNAi

Development of a stable and effective vaginal anti-HIV microbicide

New family of non-nucleoside HCMV and VZV inhibitors

NGP-1-01, a promising lead for novel neuroprotective agents

5-HT2C agonists evaluated as therapeutics for urinary disorders

Pieris and Syngenta to develop Anticalins

Recent patents disclose new therapeutic agents for diabetes

Novel agents claimed for transplant rejection and immunological disorders

Japanese approval for Follistim

Raloxifene lowers the risk of cognitive impairment in postmenopausal women

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...